Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Affimed ( (AFMD) ).
On May 13, 2025, Affimed N.V. announced its decision to file for insolvency proceedings with the local court in Mannheim, Germany, due to insufficient capital to sustain operations. The company’s financial struggles have led to concerns about its ability to continue as a going concern, prompting the management to seek insolvency protection. This move may result in the suspension and delisting of Affimed’s shares from Nasdaq, potentially affecting liquidity and trading conditions. The outcome of the insolvency proceedings remains uncertain, with potential implications for stakeholders and the company’s future operations.
The most recent analyst rating on (AFMD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Affimed stock, see the AFMD Stock Forecast page.
Spark’s Take on AFMD Stock
According to Spark, TipRanks’ AI Analyst, AFMD is a Neutral.
Affimed’s overall stock score reflects its financial struggles, with declining revenue and increasing losses being major concerns. The stock is technically weak, and the valuation is challenging due to negative earnings. Positive aspects from the earnings call, such as strategic progress in clinical trials and reduced losses, provide some optimism but are outweighed by financial and operational challenges.
To see Spark’s full report on AFMD stock, click here.
More about Affimed
Affimed N.V. is a clinical-stage immuno-oncology company based in Mannheim, Germany, focused on empowering patients to combat cancer by harnessing the potential of the innate immune system. The company’s proprietary ROCK® platform generates Innate Cell Engagers (ICE®) that target and destroy various hematologic and solid tumors. Affimed’s ICE® molecules are in clinical development, either as standalone treatments or in combination therapies.
Average Trading Volume: 104,114
Technical Sentiment Signal: Sell
Current Market Cap: $10.55M
For detailed information about AFMD stock, go to TipRanks’ Stock Analysis page.